VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension

VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension

<p>Abstract</p> <p>Background</p> <p>Pulmonary Arterial Hypertension (PAH) remains a therapeutic challenge, and the search continues for more effective drugs and drug combinations. We recently reported that deletion of the vasoactive intestinal peptide (VIP) gene caused...

Full description

Bibliographic Details
Main Authors: Szema Anthony M, Lin Richard Z, Hamidi Sayyed A, Lyubsky Sergey, Jiang Ya, Said Sami I
Format: Article
Language:English
Published: BMC 2011-10-01
Series:Respiratory Research
Subjects:
Pulmonary Hypertension
Vasoactive Intestinal Peptide
Endothelin Receptor Antagonist
Pulmonary Vascular Remodeling
Monocrotaline
Online Access:http://respiratory-research.com/content/12/1/141

Internet

http://respiratory-research.com/content/12/1/141

Similar Items